tiprankstipranks
Cautious Hold on Adaptimmune Therapeutics Amid Strategic Developments and Liquidity Concerns
PremiumRatingsCautious Hold on Adaptimmune Therapeutics Amid Strategic Developments and Liquidity Concerns
1M ago
Promising Growth Prospects and Strategic Advancements Drive Buy Rating for Adaptimmune Therapeutics
Premium
Ratings
Promising Growth Prospects and Strategic Advancements Drive Buy Rating for Adaptimmune Therapeutics
1M ago
Adaptimmune price target lowered to $1 from $1.50 at Wells Fargo
Premium
The Fly
Adaptimmune price target lowered to $1 from $1.50 at Wells Fargo
1M ago
Adaptimmune downgraded to Hold from Buy at JonesResearch
PremiumThe FlyAdaptimmune downgraded to Hold from Buy at JonesResearch
2M ago
Adaptimmune Therapeutics: Hold Rating Amid Financial Uncertainties and Strategic Challenges
Premium
Ratings
Adaptimmune Therapeutics: Hold Rating Amid Financial Uncertainties and Strategic Challenges
2M ago
Adaptimmune price target lowered to $3 from $3.50 at H.C. Wainwright
Premium
The Fly
Adaptimmune price target lowered to $3 from $3.50 at H.C. Wainwright
3M ago
Adaptimmune price target lowered to $1.50 from $2 at Wells Fargo
PremiumThe FlyAdaptimmune price target lowered to $1.50 from $2 at Wells Fargo
3M ago
Adaptimmune’s Strategic Moves in Cancer Therapy
Premium
Company Announcements
Adaptimmune’s Strategic Moves in Cancer Therapy
3M ago
Adaptimmune Therapeutics Reports Q4 2024 Business Update
Premium
Company Announcements
Adaptimmune Therapeutics Reports Q4 2024 Business Update
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100